Physician profile

Lan Luo

Cardiovascular Disease · Ocala, FL

NPI 1295938975

$11,257.51

in general payments reported to CMS, 2019-2025

48 companies · $1,081 in 2025

The $1,081 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,683.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $2,043.65 2019-2025
Astrazeneca Uk Limited $1,000.00 2022
Amgen INC. $892.84 2019-2025 Repatha, Repatha
Astrazeneca Pharmaceuticals LP $739.89 2019-2025 Brilinta, Farxiga
Janssen Pharmaceuticals, INC $620.32 2019-2024 Xarelto
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $544.55 2019-2025 Lifevest
Esperion Therapeutics, INC. $535.82 2020-2025 Nexletol
Pfizer INC. $496.91 2019-2025
Merck Sharp & Dohme LLC $456.40 2021-2025 Verquvo, Capvaxive
Boehringer Ingelheim Pharmaceuticals, INC. $435.54 2019-2025 Jardiance
Regeneron Healthcare Solutions, INC. $327.92 2019-2025 Evkeeza
Sanofi-Aventis U.S. LLC $304.60 2019-2023
Lexicon Pharmaceuticals, INC. $268.17 2023-2024 Inpefa
Abbott Laboratories $260.84 2019-2025 Aveir, Jot Dx, Mitraclip
Boston Scientific Corporation $249.33 2019-2025 Watchman Flx, Varithena Administration Pack, Resonate El Icd Vr
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Philips North America LLC $219.70 2020-2025 Ecc Solutions, (Cm9) Amb Mon & Diag Und
Alnylam Pharmaceuticals INC. $219.49 2022-2025 Onpattro, Amvuttra
E.R. Squibb & Sons, L.L.C. $207.12 2019-2024 Camzyos, Eliquis
Amarin Pharma, INC. $175.74 2019-2023
Novo Nordisk INC $152.55 2021-2024 Ozempic
Astellas Pharma US INC $109.17 2019-2021
Edwards Lifesciences Corporation $94.53 2022-2024 Sapien 3 Ultra Resilia
United Therapeutics Corporation $93.72 2024-2025 Tyvaso, Tyvaso
Medtronic Vascular, INC. $88.16 2019-2020
Lundbeck LLC $80.46 2019-2021
Impulse Dynamics (USA) INC. $76.23 2022-2023 Optimizer
Kestra Medical Technology Services, INC. $72.40 2023 Assure Wcd
Baxter Healthcare $58.33 2023-2025 Hillrom - Cardiac Ambulatory Monitor
Medtronic, INC. $58.25 2022-2023 Linq II
Abiomed $48.76 2023-2025 Impella
Ionis Pharmaceuticals, INC. $48.25 2025 Tryngolza
Bayer Healthcare Pharmaceuticals INC. $42.86 2025
Biotronik INC. $38.00 2019
Cvrx, INC. $36.88 2024 Barostim Neo System
Cashflow Solutions, LLC $36.41 2022-2025 Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White
Daiichi Sankyo INC. $22.12 2025 Injectafer
Amryt Pharma Holdings LTD $20.67 2021
Cleerly, INC. $20.07 2023 Cleerly Labs
Tactile Systems Technology INC $18.15 2025 Nimbl, Flexitouch Plus
Bard Peripheral Vascular, INC. $15.05 2024 Venclose Maven Catheter
Biocompatibles, INC. $13.98 2019
Kowa Pharmaceuticals America, INC. $13.68 2021

6 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$65,932.34 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lan Luo

$11,257.51

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk As
Context
The $1,081 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/59296/lan-luo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.